Tamas Masszi

7PUBLICATIONS
40CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInfectious diseasesTransplantation immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 10, 2026
Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis.

Hermina Sánta, Laura Regáli, László Váróczy

|Mar 22, 2023
PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content.

Ákos Nádasdi, Viktor Gál, Tamás Masszi

|Nov 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.

Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel

|Feb 23, 2022
Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients.

Ákos Nádasdi, György Sinkovits, Ilona Bobek

|Mar 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.

Jerald P Radich, Andreas Hochhaus, Tamás Masszi

|Jun 26, 2019
Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning.

Attila Tordai, Andras Bors, Katalin Piroska Kiss

Pageof 2

Frequent Collaborators

2 joint publications

Ákos Nádasdi

2 joint publications

Gábor Firneisz

1 joint publications

Attila Tordai

1 joint publications

J Valentín García-Gutiérrez